We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

15 hedge funds and large institutions have $92.3M invested in Verona Pharma in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

30% more capital invested

Capital invested by funds: $71.1M → $92.3M (+$21.2M)

7% more funds holding

Funds holding: 14 → 15 (+1)

1.48% more ownership

Funds ownership: 10.82% → 12.29% (+1.5%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.34%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
2
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$11.6M
2
FCMI
Foresite Capital Management IV
California
+$107K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$307K
2
FCMI
Foresite Capital Management III
California
-$25.1K
3
Deutsche Bank
Deutsche Bank
Germany
-$645

VRNA Hedge Fund Activity: Q3 2018 in Review

15 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2018, worth a combined $92.3M — up 30% from $71.1M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VRNA positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Abingworth, opening a new position worth an estimated $11.6M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $307K sold.

  • 15 institutional investors held Verona Pharma (VRNA) as of Q3 2018, up from 14 in Q2 2018.
  • Funds reported $92.3M of Verona Pharma stock for Q3 2018, up 30% quarter-over-quarter.
  • 2 funds opened new Verona Pharma positions in Q3 2018 and 1 closed out, a net change of +1 holder.
  • The largest Verona Pharma buyer in Q3 2018 was Abingworth, an estimated $11.6M added.
  • The largest Verona Pharma seller in Q3 2018 was Perceptive Advisors, an estimated $307K sold.

Based on aggregated 13F filings for Q3 2018.